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group, and expression of VEGF, FGF2 and type I collagen 
was upregulated. Abundant vessels in the miR-210 group 
were observed at two weeks, but there was no significant 
difference in vessel numbers between the two groups at 
six weeks. At 12 weeks, repaired Achilles tendons in the 
miR-210 group consisted of parallel and dense fibers, 
whereas wavy and loose fibers were still observed in the 
control group.
Conclusion The current study showed that single local 
injection of synthetic miR-210 promotes Achilles tendon 
healing in the early phase.
Introduction
Achilles tendon injury is a very common injury in the 
orthopaedic field, usually due to trauma or sport injury [1]. 
However, its optimal treatment is still debatable in spite 
of the high rupture incidence. Several reports comparing 
operative treatment to non-operative treatment focused 
on the rate of re-rupture and complications. Some papers 
demonstrated that non-operative treatment resulted in a 
higher incidence of re-rupture [2–4], while no significant 
difference in the re-rupture rate between non-operative 
and operative treatment was reported in several papers [5, 
6]. The most important aspect of Achilles tendon injury is 
that they heal at a slower rate than other connective tissues 
because of the reduced cellular component of the tendon 
tissue. Therefore, various studies have attempted to acceler-
ate Achilles tendon healing using drugs, cytokines and cell 
therapy [7–9].
MicroRNAs (miRNAs) are small non-coding RNA 
molecules that are well known as important key play-
ers in a variety of biological processes. miRNAs nega-
tively regulate gene expression by inhibiting translation 
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tant role in primary tendon healing, especially during 
the early healing phase. MicroRNA (miR)-210 has been 
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of collagen fiber in the miR-210 group was significantly 
higher than in the control. At two weeks, the ultimate 
failure load was significantly higher than in the control 
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or degradation of mRNA (messenger RNA) through the 
binding the 3’ untranslated region (3′ UTR) of their target 
mRNA [10–13]. miRNA plays an important role in the 
pathogenesis of many human diseases. Therefore, several 
therapeutic trials regulating endogenous miRNA in vivo 
have been conducted [14–16]. miRNA also plays a crucial 
role in the pathogenesis of disease or trauma in locomotor 
organs [17–21]. As we known, vascular supply in tendons 
is very limited and is significantly reduced after injury or 
rupture. We believe angiogenesis activation of endothelial 
cells may play an important role in promoting and regulat-
ing other biological events that can increase vascular per-
meability in the tendon healing process. MiRNA (miR)-210 
is capabile of inducing angiogenesis by targeting ephrin-
A3 (EFNA3) [22]. miR-210 is upregulated in response to 
hypoxia, which affects cell survival, migration, and differ-
entiation. Moreover, overexpression of miR-210 enhances 
the formation of capillary-like structures [23, 24]. There-
fore, our hypothesis is that administration of miR-210 can 
enhance tendon healing via acceleration of angiogenesis in 
an early phase, which will subsequently promote matura-
tion of the Achilles tendon. The purpose of this study is to 
examine the therapeutic effect of a single administration of 
miR-210 into the ruptured Achilles tendon in a rat model.
Materials and methods
Animal model
This study was reviewed and approving by the Ethics Com-
mittee for Experimental Animals of Hiroshima University 
and the animals were treated according to the guidelines of 
the Institutional Animal Care and Use Committee.
Male 12-week-old Sprague–Dawley rats weighing 
200–250 g were used in this study. The rats were housed 
under standard conditions at the Laboratory Animal Cen-
tre at the Hiroshima University. They were fed a standard 
commercial diet and water. The injured Achilles tendon 
model was created according to the previous report [7]. 
Under general anesthesia, a 3-cm longitudinal skin inci-
sion was made over the Achilles tendon of the right leg. 
The surrounding fascia was cut longitudinally, and the 
Achilles tendon and plantaris tendon were exposed. The 
Achilles tendon was cut transversely 5 mm from its cal-
caneal insertion. The Achilles tendon was repaired with 
7-0 monofilament nylon sutures using a modified Kessler-
type suture technique. The plantaris tendon was preserved. 
The wound was closed with 5–0 monofilament nylon 
sutures. After surgery, 30 μl of atelocollagen (Koken, 
Tokyo, Japan)/double stranded (ds) RNA (atelocolla-
gen 15 μl; dsRNA 20 μg) was injected percutaneously 
into the repaired tendon (Fig. 1). Ds miR-210 (sequences 
66-CUG-UGC-GUG-UGA-CAG-CGG-CUG-A-87 and 
87-AGC-CCC-UGC-CCA-CCG-CAC-ACU-G-66 labeled 
with FAM, B-Bridge International) was injected into the 
repaired tendon site in the miR-210 group, and non-func-
tional ds RNA (siRNA negative control, B-bridge Inter-
national; ds Nega) was injected in the control group. The 
rats without any ds RNA injection after surgery were also 
evaluated as the non-injection group. The rats were placed 
in their cages and afforded unrestrained mobility. At 24 h, 
3 days, and 2, 6 and 12 weeks after operation all rats were 
killed by overdose injection of anesthesia. The Achil-
les tendon was removed with the attached calcaneal bone 
and dissected from other surrounding tissue and prepared 
for histological evaluation, gene expression analysis, and 
mechanical testing. Five rats in each group were used to 
test tensile strengths, and five other rats were used to test 
gene expression. The remaining rats in each group were 
used for histological evaluation.
Histological analysis
At 2, 6 and 12 weeks after surgery, 5 rats in each group 
at each time point were sacrificed. Then, Achilles tendons 
were harvested and quickly embedded in Tissue Freezing 
Medium (Triangle Biomedical Sciences, Durham, NC, 
USA), snap-frozen in liquid nitrogen. Sections 6 μm thick 
were prepared and Masson trichome staining was per-
formed. The specimens were examined in a random order 
with a microscope and two observers (MAU, TS) evalu-
ated the specimens according to an arbitrary scoring system 
from 1 to 5, where 1 represented an immature loose cal-
lus and 5 represented a dense organized fibrous tissue with 
5mm
dsRNA/ 
Atelocollagen
Complex 
20μg/15μl
Plantaris
tendon
Fig. 1  Experimental procedure scheme
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mostly parallel fibers, according to the previous report [21]. 
Five microscopic areas from each specimen at ×200 mag-
nification were randomly chosen and the diameter of newly 
formed collagen fiber was measured by the two authors 
(MAU, TN) at two and six weeks using a digital micro-
scope (BZ-9000, Keyence, Japan).
To evaluate the distribution of the injected ds miRNA, 
rats were sacrificed 24 h after injection and 6-μm serial sec-
tions were mounted on saline-coated glass slides, air-dried, 
and fixed with 4.0 % paraformaldehyde at 4 °C for 5 min. 
Then, 4′,6-diamidino-2-phenylindole (DAPI) solution was 
applied for 5 min for nuclear staining. FAM-labeled miR-
210 in Achilles tendon specimens was detected using fluo-
rescence microscopy.
Immunohistochemistry analysis
For immunohistochemistry staining of Isolectin B4, VEGF, 
FGF2 and Collagen type I, specimens were fixed with 
4.0 % paraformaldehyde at 4 °C for 5 min. After block-
ing by horse serum (Vector Laboratories, Bur- lingame, 
California), specimens were stained with rabbit poly-
conal anti-VEGF or anti basic FGF antibody (Abcam, 
Cambridge, Massachusetts, concentration 1:100), goat 
polyelonal anti-collagen type I antibody (Santa Cruz Bio-
technology, Santa Cruz, California; concentration 1:50), 
or fluorescein-labeled GSL I-isolectinB4 (Vector Labora-
tories, Burlingam, California; concentration 1:100) The 
secondary antibodies used were Alexa Fluor 488-conjun-
gated or Alexa Fluor 568-conjungated goat anti-rabbit IgG 
for VEGF and FGF2, and Alexa 488-conjugated or Alexa 
568-conjungated rabbit anti-goat IgG for collagen type I 
(all from Molecular Probes/Invitrogen, Carlsbad, Califor-
nia). DAPI solution was applied for 5 min to detect nuclear 
staining. The negative control was prepared in the same 
manner without the primary antibody. For evaluating newly 
formed vessels, five microscopic areas (250 × 250 μm) 
from each specimen at ×200 magnification were randomly 
chosen. Capillaries were recognized as tubular structures 
positive for isolectin B4, and counted by the two authors 
(MAU, TN).
Mechanical testing
For testing mechanical properties at two and six weeks, a 
conventional tensile tester (1840 NT/500; AIKOH Engi-
neering, Osaka, Japan) was used. All of the extra soft tissue 
and hard tissue was removed from the calcaneal or Achil-
les tendon complex by blunt and/or sharp dissection. The 
calcaneus-Achilles tendon complex was fixed between two 
metal clamps and pulled at a constant speed of 200 mm/
min vertically until rupture. The maximum load recorded 
was recognized as the ultimate tensile strength. In addition, 
the calcaneus-Achilles tendon complex from other normal 
rats were measured as normal tendons.
Quantitative real-time PCR
Total RNA was isolated from repaired Achilles tendon site 
using TRIzol. Complementary DNA was synthesized using 
"Ready to Go You-Prime First-Strand Beads" (GE Health-
care, Chalfot, UK) with total RNA (1 μg) and oligo (dT) 
primers. For miRNA expression analysis, reverse tran-
scriptase reactions of mature miRNAs contained a sample 
of total RNA, 50 nM of stem-loop RT primer, 10 × RT 
buffer, 100 mM of each dNTP, 50 U/μl of MultiScribe 
Reverse Transcriptase, and 20 U/μl of RNase inhibitor. 
15-μl reactions were incubated in a thermocycler (Bio-
Rad, Hercules, CA). Real-time quantitative PCR was car-
ried out using TaqMan Gene Expression Assay probes for 
rno-miR-210, snoRNA-135, VEGF, COL1A1, FGF2 and 
ACTB. The expression levels for each gene were assessed 
relative to the expression of snoRNA-135 for miR-210, 
and ACTB for other genes. A threshold cycle (CT) was 
observed in the exponential amplification phase, and quan-
tification of relative expression levels was performed using 
standard curves for target genes and the endogenous con-
trol. Geometric means were used to calculate the ΔΔCT 
(delta–delta CT) values and expressed as 2−ΔΔCT. The value 
of each control sample was set at one and used to calculate 
the fold-change of target genes.
Statistical analysis
All results in this study were expressed as the 
mean ± standard deviation (SD). Comparison among the 
three groups was done using the Tukey–Kramer post hoc 
test. A p value of <0.05 was consider statistically signifi-
cant. All data were calculated and shown as value ±SD.
Results
Administration of ds miR-210 could enhance 
morphological and functional recovery
Per their gross appearance at two weeks, the Achilles tendon 
surfaces in the control group were irregular and delle was 
observed in the repaired site. On the other hand, repaired 
Achilles tendon surfaces in the miR-210 treated group were 
smoother and bulkier than in the control group. Histologi-
cal analyses of Masson trichrome staining demonstrated 
that the injury site was filled by a dense organized fibrous 
tissue with mostly parallel fibers in the miR-210 group, 
while immature loose fibrous tissue was observed in the 
control and non-injection groups (Fig. 2a). At six weeks, 
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abundant collagen fibers with little fibrous tissue occupied 
the injured site in the miR-210 group, while the abundant 
loose fibrous tissue still remained in the control and non-
injection groups (Fig. 2a). The histological score of the 
miR-210 group (4.4 ±0.2 points) was significantly higher 
than the control (1.4 ±0.2 points) and non-injection groups 
(1.4 ±0.5) at two weeks, and the histological score in the 
miR-210 group was significantly higher than that in the con-
trol and non-injection groups (non-injection group, 1.8 ±0.8 
points; control group, 1.8 ±0.8 points; miR-210 group, 
4.6 ±0.5 points) at six weeks. The mean collagen fiber 
diameter in the miR-210 group was significantly higher 
than that in the control (non-injection group, 2.4 ±0.2 μm; 
control group, 2.5 ±0.3 μm; miR-210 group, 4.0 ±0.2 μm) 
(p < 0.05) at two weeks, and the mean collagen fiber in the 
miR-210 group was significantly higher than that in the 
controls (non-injection group, 4.4 ±0.4 μm; control group, 
4.2 ±0.3 μm; miR-210 group, 6.0 ±0.3 μm) (p < 0.05) at 
six weeks (Fig. 2b). FAM-labeled dsmiR-210 was detected 
in the tendon near the injured site and around the tendon 
(Fig. 2c). The ultimate failure load of the Achilles tendon 
in the miR-210 group (25.3 ±7.3 N) was significantly 
higher than that in the non-injection group (13.2 ±1.7 N) 
and control group (14.6 ±1.7 N) at two weeks after local 
injection (p < 0.05) (Fig. 3). At six weeks, there was no 
significant difference in the ultimate failure load between 
both groups (p = 0.453), but the ultimate failure load in 
the miR-210 group (73.0 ±22.4 N) was likely to be higher 
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Fig. 2  a Masson trichrome staining of repaired site in the non-injec-
tion, control and miR-210 groups at two and six weeks. Bars rep-
resent 100 μm. b Collagen fiber diameter in all groups at two and 
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than that in the non-injection (65.9 ±17.3 N) and control 
groups (70.4 ±22.4 N). In all groups, the failure site was the 
repaired site in all specimens. These findings indicate that 
single local injection of ds miR-210 could enhance morpho-
logical and functional recovery at two weeks.
To examine the effect of miR-210 administered on angi-
ogenesis during an early phase, immunohistochemistry of 
isolectin B4 was performed. In thew miR-210 group, abun-
dant vessels in the repaired site were observed while there 
were few newly-formed vessels in the non-injection and 
control groups (Fig. 4a). The capillary density in miR-210 
group was significantly higher than that in the non-injection 
and control groups (non-injection group, 31.4 ±5.3; con-
trol group, 32.6 ±8.3; miR-210 group, 172.1 ±12.7 capil-
lary profiles per mm2, p < 0.05). Although miR-210 pro-
motes healing by angiogenesis during the early phase, there 
was no significant difference in the number of blood ves-
sels between all groups (non-injection group, 75.5 ±4.3; 
control group, 76.2 ±7.6; miR-210 group, 84.5 ±15.4 cap-
illary profiles per mm2) at six weeks, indicating blood ves-
sel retraction during a subsequent remodeling phase, during 
tendon maturation by miR-210 injection (Fig. 4b).
Gene expression analysis
Firstly, the expression level of miR-210 at three days after 
injection was evaluated by real-time PCR. The expression 
of mature rno-miR-210 was significantly upregulated in the 
miR-210 group compared to the non-injection and control 
gropus (p < 0.05) (Fig. 5a). VEGF, which is an important 
factor of angiogenesis in the healing process, was upregu-
lated in the miR-210 group as compared to the non-injec-
tion and control groups (Fig. 5b). Also, expression of FGF2 
and Col1a1 in the miR-210 group was significantly higher 
than in the non-injection and control groups (Fig. 5c, d). 
The immunohistochemistry of VEGF, FGF2 and type I 
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Fig. 4  a Immunohistochemistry of isolectin B4 at two and six weeks. Bars represent 100 μm. b The number of blood vessels in the non-injec-
tion, control and miR-210 groups at two and six weeks. *p < 0.05. NS no significant difference
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collagen two weeks after injection was more expressed at 
the injured sites in the miR-210 group as compared to the 
control group (Fig. 6).
Administration of ds miR-210 can promote maturation 
of the Achilles tendon
At 12 weeks, repaired Achilles tendons in the miR-210 
group consisted of parallel and dense fibers, whereas the 
control group still exhibited wavy and loose fibers, although 
newly-formed collagen fibers in the Achilles tendon in both 
groups were remodeled and had matured (Fig. 6).
Discussion
Vascular supply plays an important role in primary tendon 
healing [26, 27]. Tendon healing undergoes three phase, 
including an inflammatory phase, a proliferative phase, and 
a remodeling phase [28]. During these phases, especially at 
the early stage, blood supply provides not only cell infiltra-
tion, including inflammatory cells and fibroblasts, but also 
supplies reparative factors such as multiple growth factors, 
oxygen, and so on. It is expected that the promotion of neo-
vascularization accelerates tendon healing by up-regulation 
of endogenous reparative factors. Growth factors such as 
VEGF, TGF-β1, PDGF, and FGF2 also have multiple sig-
nificant roles in tendon healing [29]. During the tendon 
healing process, each growth factor has a crucial func-
tion at different stages and work in cooperation with other 
growth factors during such. Several studies have attempted 
to improve the primary tendon healing process by apply-
ing exogenous growth factor in animal models, demonstrat-
ing enhanced tendon healing [7]. In most of these studies, 
however, the application of a single growth factor was con-
ducted. The application of a single exogenous growth factor 
Fig. 5  Gene expression 
analysis of miR-210, VEGFA, 
FGF2 and Col1a1 by real-time 
PCR three days after injection. 
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might not be enough to further improve and accelerate 
physiological tendon healing. Notably, one miRNA has a 
hundred target genes estimated by computational analysis, 
meaning miRNA can regulate many gene networks simul-
taneously. This could be one of the advantages of miRNA 
therapy. It has been reported that miRNA-210 plays a cru-
cial role in angiogenesis in response to hypoxia via target-
ing Ephrin-A3, E2F3, NPTX1, RAD52, ACVR1B, MNT, 
CASP8AP2, FGFRL1, and HOXA-1 [22–24]. Hu et al. 
[28] demonstrated that local injection of ds miR-210 into 
the myocardium improves cardiac function through angio-
genesis, inhibiting apoptosis. Shoji et al. [16] reported that 
intra-articular injection of ds miR-210 for partial rupture of 
the anterior cruciate ligament accelerated ligament healing 
in a rat model. In the orthopaedic field, reports of therapeu-
tic trials in vivo using several miRNAs have increased. It 
has been reported that local injection of muscle-specific 
miRNAs accelerates muscle regeneration in a rat muscle 
injury model [21]. Systemic injection of miR-146a amelio-
rated joint destruction in a collagen-induced mouse model.
Masson trichrome staining revealed the collagen fibers in 
the miR-210 treated group become more aligned and denser 
than that in the control group at two weeks. In immuno-
histochemistry analysis of type I collagen, the synthesis of 
type I collagen in the miR-210-treated group was higher 
than that in the control group, which usually begins at 
about six weeks, during the remodeling phase. In previous 
reports, TGF-β1 promoted collagen synthesis in repaired 
Achilles tendons in rats, subsequently increasing the ten-
sile strength at two and four weeks [30]. Our mechani-
cal testing results showed that administering ds miR-210 
increased the tensile strength in the repaired Achilles ten-
don at two weeks after surgery. Improvement during the 
early phase of primary tendon healing has become more 
and more important since several clinical studies have indi-
cated the benefit of early mobilization after surgery. The 
most significant result of the present study, therefore, is 
that local injection of ds miR-210 into an injured Achilles 
tendon can give rise to higher tensile strength and aid the 
histological healing process of advanced tissue during the 
early phase, leading to more mature Achilles tendon heal-
ing at six weeks (Fig. 7).
Tendons are largely avascular. The in-growth of ves-
sels contributes to tendon repair during the early phase but 
over-vasculature in the tendon may cause chronic tendi-
nopathy. In our results, abundant blood vessels at the repair 
site in the miR-210 group were observed, but the blood 
vessels retracted during the subsequent remodeling phase, 
FGF2 FGF2 / DAPIdsmiR-210
control FGF2 FGF2 / DAPIVEGF VEGF / DAPIcontrol control
dsmiR-210 VEGF dsmiR-210 VEGF / DAPI
control Col1 Col1 / DAPI
dsmiR-210 Col1 Col1 / DAPI
control
dsmiR-210 Negative control
Non-injection Non-injection
Non-injection
VEGF / DAPI FGF2 / DAPI
Col1 / DAPI
Fig. 6  Immunohistochemical analysis of VEGFA, FGF2 and type I collagen two weeks after injection. Bar represents 100 μm
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indicating that single local injection of ds miR-210 did not 
induce lasting over-vasculature, resulting in impaired ten-
don function. Blood vessel retraction during the latter phase 
may be due to the acceleration of remodeling induced by 
miR-210 injection.
There are several limitations to this study. First, it is 
unclear what kind of cells miR-210 affect. FAM-labeled 
miR-210 was detected in the tendon and surrounding tis-
sue. It has been reported that miR-210 can function in the 
endothelial cells. Therefore, miR-210 might be taken up in 
the endothelial cells around the repaired tendon site, and 
there was a possibility that miR-210 might work in fibro-
blasts in the tendon. Second, the precise molecular mecha-
nism by which miR-210 enhances Achilles tendon healing 
has not been elucidated. In our study, VEGF and FGF2, 
which play important roles in angiogenesis, were upregu-
lated by miR-210, and the acceleration of tendon healing 
might enhance collagen type I synthesis. However, its pro-
cess, including changing the expression pattern of miR-210 
target genes, could not be elucidated. miRNAs have hun-
dreds of target gene, as determined by computational analy-
sis. Therefore, it is challenging to elucidate the mechanism 
completely. These results suggest that administrated miR-
210, which was taken up or which upregulated the expres-
sion of the endogenous miR-210 in the injured Achilles 
tendon, could have upregulated VEGF and FGF2 expres-
sion, and subsequently induced type I collagen, which is 
a main functional component of tendons during the early 
tendon healing phase. Finally, there was a possibility that 
the non-specific response, such as an unexpected vascu-
lar or immune response to the injected synthetic miR-210, 
could of enhanced Achilles tendon healing. However, we 
created a non-RNA injection control model and it exhibited 
the same results of non-specific, functional ds RNA. These 
data and the previous report of Shoji et al. suggest that 
miR-210 injection had a specific effect on enhancement of 
Achilles tendon healing.
In conclusion, our study shows the potential of adminis-
tering ds miR-210 for the acceleration of tendon repair. It 
is speculated that miR-210 accelerates neovascularization 
and, consequently, induces a microenvironment conducive 
to tendon healing during the early phase. Nevertheless, 
the details of this mechanism remain unclear. Single local 
injection of ds miR-210 may become a new therapeutic 
strategy for promoting tendon healing.
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